METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
    6.
    发明公开
    METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE 审中-公开
    肾损伤和肾功能衰竭的诊断和预后的方法和组合物

    公开(公告)号:EP2347260A2

    公开(公告)日:2011-07-27

    申请号:EP09822670.7

    申请日:2009-10-21

    IPC分类号: G01N33/53 C12Q1/68

    摘要: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble CD44 antigen, Angiopoietin-1, soluble Angiopoietin-1 receptor, C-X-C chemokine motif 5, soluble Endoglin, soluble Tumor-associated calcium signal transducer 1, Erythropoietin, soluble Fractalkine, Heme oxygenase 1, soluble Interleukin-1 receptor type II, soluble Interleukin-6 receptor subunit-alpha, Lymphotactin, Lymphotoxin-alpha, Stromelysin- 1, C-C motif chemokine 22, C-C motif chemokine 5, and Thrombospondin-1 as diagnostic and prognostic biomarkers in renal injuries.

    摘要翻译: 本发明涉及用于监测,诊断,预后和确定患有或怀疑患有肾损伤的受试者的治疗方案的方法和组合物。 具体而言,本发明涉及使用检测选自以下的一种或多种标记物的测定法:可溶性CD44抗原,促血管生成素-1,可溶性促血管生成素-1受体,CXC趋化因子基序5,可溶内皮糖蛋白,可溶性肿瘤相关钙信号转导子 1,促红细胞生成素,可溶性Fractalkine,血红素加氧酶1,可溶性白细胞介素-1受体II型,可溶性白细胞介素-6受体亚单位-α,淋巴肿瘤素,淋巴毒素-α,溶基质素-1,CC基序趋化因子22,CC基序趋化因子5和血小板反应蛋白 -1作为肾损伤的诊断和预后生物标志物。

    METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
    7.
    发明公开
    METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE 审中-公开
    肾损伤和肾功能衰竭的诊断和预后的方法和组合物

    公开(公告)号:EP3246707A1

    公开(公告)日:2017-11-22

    申请号:EP17174892.4

    申请日:2009-10-21

    IPC分类号: G01N33/68

    摘要: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Tissue inhibitor of metalloproteinase 2, and optionally further one or more markers of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2 , soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

    摘要翻译: 本发明涉及用于监测,诊断,预后和确定患有或怀疑患有肾损伤的受试者的治疗方案的方法和组合物。 特别地,本发明涉及使用检测金属蛋白酶2的组织抑制剂和任选地另外一种或多种细胞质天冬氨酸转氨酶标记物,可溶性肿瘤坏死因子受体超家族成员5,可溶性CD40配体,可溶性CXC基元趋化因子16,S100- A12,Eotaxin,可溶性E-选择素,纤连蛋白,粒细胞集落刺激因子,粒细胞 - 巨噬细胞集落刺激因子,肝素结合生长因子2,可溶性肝细胞生长因子受体,白细胞介素-1受体拮抗剂,白细胞介素-1β,白细胞介素 -10,白细胞介素15,白细胞介素-3,髓过氧化物酶,Nidogen-1,可溶性低密度脂蛋白受体1,Pappalysin-1,可溶性P-选择素糖蛋白配体1,Antileukoproteinase,可溶性Kit配体,金属蛋白酶组织抑制剂1, 可溶性肿瘤坏死因子,可溶性血管细胞粘附分子1和血管内皮生长因子A作为诊断和预后生物标志物 s肾脏损伤。